Predicting Progression to Mild Cognitive Impairment

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Despite much attention to the use of biomarkers for predicting Alzheimer disease, little information is available at the individual level. We used the population-based Mayo Clinic Study of Aging to estimate absolute risk of cognitive impairment by biomarker group. Risk increased with age and any biomarker abnormality. For example, a 75-year-old with abnormal amyloid and cortical thinning biomarkers has about a 20% chance of cognitive impairment by age 80 years, whereas with normal biomarkers the chance is <10%. Persons with only one abnormal biomarker had similar intermediate risks. ANN NEUROL 2019;85:155–160.

Original languageEnglish (US)
Pages (from-to)155-160
Number of pages6
JournalAnnals of Neurology
Volume85
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Biomarkers
Amyloid
Cognitive Dysfunction
Alzheimer Disease
Population

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

@article{309692e4354549e5ad5271560af92b1f,
title = "Predicting Progression to Mild Cognitive Impairment",
abstract = "Despite much attention to the use of biomarkers for predicting Alzheimer disease, little information is available at the individual level. We used the population-based Mayo Clinic Study of Aging to estimate absolute risk of cognitive impairment by biomarker group. Risk increased with age and any biomarker abnormality. For example, a 75-year-old with abnormal amyloid and cortical thinning biomarkers has about a 20{\%} chance of cognitive impairment by age 80 years, whereas with normal biomarkers the chance is <10{\%}. Persons with only one abnormal biomarker had similar intermediate risks. ANN NEUROL 2019;85:155–160.",
author = "Petersen, {Ronald Carl} and Lundt, {Emily S.} and Therneau, {Terry M} and Weigand, {Stephen D.} and Knopman, {David S} and Mielke, {Michelle M} and Roberts, {Rosebud O} and Val Lowe and Machulda, {Mary Margaret} and Kremers, {Walter K} and Geda, {Yonas Endale} and Jack, {Clifford R Jr.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/ana.25388",
language = "English (US)",
volume = "85",
pages = "155--160",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Predicting Progression to Mild Cognitive Impairment

AU - Petersen, Ronald Carl

AU - Lundt, Emily S.

AU - Therneau, Terry M

AU - Weigand, Stephen D.

AU - Knopman, David S

AU - Mielke, Michelle M

AU - Roberts, Rosebud O

AU - Lowe, Val

AU - Machulda, Mary Margaret

AU - Kremers, Walter K

AU - Geda, Yonas Endale

AU - Jack, Clifford R Jr.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Despite much attention to the use of biomarkers for predicting Alzheimer disease, little information is available at the individual level. We used the population-based Mayo Clinic Study of Aging to estimate absolute risk of cognitive impairment by biomarker group. Risk increased with age and any biomarker abnormality. For example, a 75-year-old with abnormal amyloid and cortical thinning biomarkers has about a 20% chance of cognitive impairment by age 80 years, whereas with normal biomarkers the chance is <10%. Persons with only one abnormal biomarker had similar intermediate risks. ANN NEUROL 2019;85:155–160.

AB - Despite much attention to the use of biomarkers for predicting Alzheimer disease, little information is available at the individual level. We used the population-based Mayo Clinic Study of Aging to estimate absolute risk of cognitive impairment by biomarker group. Risk increased with age and any biomarker abnormality. For example, a 75-year-old with abnormal amyloid and cortical thinning biomarkers has about a 20% chance of cognitive impairment by age 80 years, whereas with normal biomarkers the chance is <10%. Persons with only one abnormal biomarker had similar intermediate risks. ANN NEUROL 2019;85:155–160.

UR - http://www.scopus.com/inward/record.url?scp=85059612078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059612078&partnerID=8YFLogxK

U2 - 10.1002/ana.25388

DO - 10.1002/ana.25388

M3 - Article

VL - 85

SP - 155

EP - 160

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 1

ER -